Ambry Experts Provide Insight on Genetic Testing’s Clinical Utility at the 2017 SSO Annual Cancer Symposium

blog image

Ambry has continued to provide clinicians with the most relevant and useful information to encourage education about the benefits of genetic testing for patients and ways to streamline genetic testing in clinical practice.

At the 2017 SSO Annual Cancer Symposium, Ambry hosted the presentation “On the Cutting Edge: Sharpening Your Genetic Awareness with Impactful Tools for your Practice,” featuring speakers Robina Smith, MD, EMBA, Ambry’s Director of Medical Affairs, and Michelle Jackson, MS, CGC, Ambry’s Oncology Product Manager, who discussed several educational objectives on streamlining genetic testing.

Dr. Smith highlighted the clinical utility of genetic testing by providing four case examples on four different genes. She walked the audience through the presentation of a patient in a clinic setting while highlighting the typical vital signs utilized by clinicians, while incorporating genetic testing.

“For all physicians, it is expected that an elevated risk (i.e. vital signs, signs & symptoms) of any disease, for which there is screening, prevention and treatment, needs immediate action,” said Dr. Smith. “The same philosophy applies to a deleterious genetic mutation. Think of assessing your patients risk for hereditary cancers as the ‘6th vital sign.’”

Ms. Jackson spoke on several of Ambry’s genetic testing panels that offer a broad scope of results. The panels, which highlighted many options from the hereditary cancer test menu, offer a comprehensive testing option for clinicians and their patients.

“At Ambry, we are driven to give physicians the most advanced testing information available so they can determine the best treatment options for their patients,” said Ms. Jackson.  “Conveying our mission, history, and comprehensive hereditary cancer testing menu demonstrates why we do what we do and who we do it for. We ultimately want to help patients find answers.”

{Learn more from Ms. Jackson: “Research Shows BRCA2 May Be Linked To Brain Tumors”}

Dr. Smith also focused on the utility of several clinical tools, which were incorporated throughout the presentation with case examples. For instance, if a clinician sees a healthy woman inquiring about hereditary breast and ovarian cancer, Dr. Smith recommended utilizing Ambry’s risk assessment models through Progeny and Clinician Management Resources, which follow National Comprehensive Cancer Network® (NCCN®) guidelines.

Ambry offers a variety of clinical tools and resources that can aid clinician’s knowledge base and patient communication. For more information about some of the available tools, click here.

In addition, Ambry offers several comprehensive genetic testing options for a wide variety of hereditary cancers. Panels such as CancerNext and CancerNext-Expanded analyze genes that are associated with hereditary breast, ovarian, uterine, prostate, colorectal and other cancers.

For a complete list of Ambry’s hereditary cancer testing options, click here.

 



Author

DISCLAIMER: THIS BLOG DOES NOT PROVIDE MEDICAL ADVICE

The information, including but not limited to, text, graphics, images and other material contained on this blog are for informational purposes only. The purpose of this blog is to promote broad understanding and knowledge of various health topics. It is not intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified health care provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this blog. Ambry Genetics Corporation does not recommend or endorse any specific tests, physicians, products, procedures, opinions or other information that may be mentioned on this blog. Reliance on any information appearing on this blog is solely at your own risk.

Subscribe

Subscribe to our blog for updates, sent out every month.

Click Here

Tags For This Post